Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Platform trials.
Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. Roustit M, et al. Among authors: porcher r. Therapie. 2023 Jan-Feb;78(1):29-38. doi: 10.1016/j.therap.2022.12.003. Epub 2022 Dec 5. Therapie. 2023. PMID: 36529559 Free PMC article.
Les essais plateformes.
Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. Roustit M, et al. Among authors: porcher r. Therapie. 2023 Jan-Feb;78(1):19-28. doi: 10.1016/j.therap.2022.11.011. Epub 2022 Dec 5. Therapie. 2023. PMID: 36581520 Free PMC article. French.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. Among authors: porcher r. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, Porcher R, Thiébaut R, Vray M, Zohar S, Cochat P, Le Guludec D. Vanier A, et al. Among authors: porcher r. BMJ Evid Based Med. 2024 Jan 19;29(1):1-5. doi: 10.1136/bmjebm-2022-112091. BMJ Evid Based Med. 2024. PMID: 36788020 Free PMC article. No abstract available.
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial.
Lacombe K, Hueso T, Porcher R, Mekinian A, Chiarabini T, Georgin-Lavialle S, Ader F, Saison J, Martin-Blondel G, De Castro N, Bonnet F, Cazanave C, Francois A, Morel P, Hermine O, Pourcher V, Michel M, Lescure X, Soussi N, Brun P, Pommeret F, Sellier P, Rousset S, Piroth L, Michot JM, Baron G, de Lamballerie X, Mariette X, Tharaux PL, Resche-Rigon M, Ravaud P, Simon T, Tiberghien P. Lacombe K, et al. Among authors: porcher r. BMJ Med. 2023 Oct 27;2(1):e000427. doi: 10.1136/bmjmed-2022-000427. eCollection 2023. BMJ Med. 2023. PMID: 37920150 Free PMC article.
Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry.
Nguyen Y, Mariette X, Gottenberg JE, Iudici M, Morel J, Vittecoq O, Constantin A, Flipo RM, Schaeverbeke T, Sibilia J, Ravaud P, Porcher R, Seror R. Nguyen Y, et al. Among authors: porcher r. Rheumatology (Oxford). 2023 Sep 19:kead495. doi: 10.1093/rheumatology/kead495. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37725356
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
Cavillon A, Pouessel D, Houédé N, Mathevet F, Dauxois JY, Chevreau C, Culine S, Delord JP, Porcher R, Filleron T. Cavillon A, et al. Among authors: porcher r. Eur Urol. 2024 Mar;85(3):293-300. doi: 10.1016/j.eururo.2023.02.011. Epub 2023 Feb 26. Eur Urol. 2024. PMID: 36849297
Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.
Cavillon A, Porcher R, Filleron T. Cavillon A, et al. Among authors: porcher r. Eur Urol. 2023 Jul;84(1):e22-e23. doi: 10.1016/j.eururo.2023.04.016. Epub 2023 Apr 27. Eur Urol. 2023. PMID: 37120335 No abstract available.
485 results